Lab-growing cardiomyocytes have been transplanted into a human patient for the first time in medical history, according to a report from the Japan Times.

Scientists have uncovered a potential new treatment for heart failure with preserved ejection fraction (HFpEF)—and it’s one that already exists.

A cross-structural analysis published in Mayo Clinic Proceedings this January independently links diabetes to the development of heart failure, suggesting diabetic cardiomyopathy is a real—and growing—issue in the U.S.

Drugmaker AstraZeneca announced Jan. 6 that its SGLT2 inhibitor dapagliflozin, sold commercially as Farxiga, had been granted Priority Review by the FDA for patients with heart failure with reduced ejection fraction.

Diagnosed cases of chronic heart failure are expected to number 32 million by 2028, according to a report from analytics company GlobalData.

Beta-blocker use was linked to an increased risk of heart failure hospitalizations in a recent study of patients with “stiff heart” HF—a concerning finding considering the majority of such patients take the drugs as part of their care regimen.

Novoheart, a Vancouver-based stem cell biotech company, is pairing with biopharmaceutical giant AstraZeneca to develop the world’s first human-specific in vitro functional model of heart failure with preserved ejection fraction.

Brushing teeth three or more times a day could dramatically lower a person’s risk for CVDs like heart failure and atrial fibrillation, according to preliminary research out of Ewha Womans University in Seoul, South Korea.